Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole + ribociclib vs. fulvestrant + letrozole + ribociclib in HR+ HER2- metastatic breast cancer
KCT0008051Phase 2Not yet recruiting
- Sponsor
- Korea University Guro Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ribociclib in breast cancer (2 arms), sponsored by Korea University Guro Hospital. Planned start May 2023; status: not yet recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0008051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008051.